LINDA KELLY: Open Payments
NPI 1538858089 · PIKESVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,883 in 176 payments from 16 companies in 2025. Trend: 2023 $970 · 2024 $2,113 · 2025 $2,883
Food & beverage: $2,883
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 71 | $983 |
| GENZYME CORPORATION | 15 | $309 |
| Janssen Biotech, Inc. | 12 | $279 |
| Madrigal Pharmaceuticals | 11 | $235 |
| Ipsen Biopharmaceuticals, Inc | 13 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $180 |
| Gilead Sciences, Inc. | 13 | $146 |
| PFIZER INC. | 6 | $102 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $83 |
| Regeneron Healthcare Solutions, Inc. | 4 | $83 |
Products named: RINVOQ, DUPIXENT, TREMFYA, REZDIFFRA, CREON, IQIRVO, ENTYVIO, LINZESS.
Industry payments across MD — which companies pay providers there.
